{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:21:51Z","timestamp":1780474911884,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","award":["68322757"],"award-info":[{"award-number":["68322757"]}],"id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transthyretin amyloidosis (ATTR) is a multisystem disease caused by the deposition of fibrillar protein in organs and tissues. ATTR genotypes and phenotypes are highly heterogeneous. We present data on physical signs and symptoms, cardiac and neurological assessments and genetic profile of patients enrolled in the Transthyretin Cardiac Amyloidosis Registry of the State of S\u00e3o Paulo, Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six hundred-forty-four patients were enrolled, 505 with the variant form (ATTRv) and 139 with wild-type (ATTRwt). Eleven different mutations were detected, the most common being Val50Met (47.5%) and V142Ile (39.2%). Overall, more than half of the patients presented cardiac involvement, and the difference in this proportion between the ATTRv and ATTRwt groups was significant (43.9 vs. 89.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The prevalence of the neurological phenotype also differed between ATTRv and ATTRwt (56.8 vs. 31.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The mixed phenotype was found in 25.6% of the population, without a significant difference between ATTRv and ATTRwt groups. A group of patients remained asymptomatic (10.4%), with a lower proportion of asymptomatic ATTRwt patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study details the clinical and genetic spectrum of patients with ATTR in S\u00e3o Paulo, Brazil. This preliminary analysis highlights the considerable phenotypic heterogeneity of neurological and cardiac manifestations in patients with variant and wild-type ATTR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03281-z","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T05:01:49Z","timestamp":1721451709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of S\u00e3o Paulo, Brazil (REACT-SP)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-8805","authenticated-orcid":false,"given":"F\u00e1bio","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-1297","authenticated-orcid":false,"given":"Georgina del Cisne Jad\u00e1n","family":"Luzuriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6477-8741","authenticated-orcid":false,"given":"Guilherme Wesley Peixoto","family":"da Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edileide Barros","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzira Alves Siqueira","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane Vieira Scarlatelli","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Rizzi","family":"Coelho-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murillo Oliveira","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Vellosa","family":"Schwartzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrigo","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vinicius","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"3281_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","volume":"27","author":"M Russo","year":"2020","unstructured":"Russo M, Obici L, Bartolomei I, et al. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid. 2020;27:259\u201365.","journal-title":"Amyloid"},{"key":"3281_CR2","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118:3517\u201335.","journal-title":"Cardiovasc Res"},{"key":"3281_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/labinvest.3700107","volume":"84","author":"M Sousa","year":"2004","unstructured":"Sousa M, Ferr\u00e3o J, Fernandes R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest. 2004;84:865\u201373.","journal-title":"Lab Invest"},{"key":"3281_CR4","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52:1913\u201326.","journal-title":"Biochemistry"},{"key":"3281_CR5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554\u201368.","journal-title":"Eur Heart J"},{"key":"3281_CR6","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy \u2013 from diagnosis to prognosis. Eur J Heart Fail. 2022;24:2355\u201363.","journal-title":"Eur J Heart Fail"},{"key":"3281_CR7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"3281_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1590\/0004-282x20180156","volume":"77","author":"MW Cruz","year":"2019","unstructured":"Cruz MW, Pinto MV, Pinto LF, et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr. 2019;77(2):96\u2013100.","journal-title":"Arq Neuropsiquiatr"},{"key":"3281_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2016;68:161\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"3281_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MAJ.0b013e318141f8eb","volume":"334","author":"ASA Naderi","year":"2007","unstructured":"Naderi ASA, Farsian FN, Igarashi P. Gastrointestinal amyloidosis associated with transthyretin Phe64Ser mutation. Am J Med Sci. 2007;334:219\u201321.","journal-title":"Am J Med Sci"},{"key":"3281_CR11","unstructured":"Rowczenio D, Wechalekar A. Mutations in Transthyretin Gene (TTR). Mutations in Hereditary Amyloidosis. 2015."},{"key":"3281_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1212\/WNL.51.5.1462","volume":"51","author":"CJ Klein","year":"1998","unstructured":"Klein CJ, Nakumura M, Jacobson DR, et al. Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Neurology. 1998;51:1462\u20134.","journal-title":"Neurology"},{"key":"3281_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1515\/tnsci-2022-0219","volume":"13","author":"X Yan","year":"2022","unstructured":"Yan X, Hong M, Zhou Z, et al. A patient with hereditary transthyretin amyloidosis involving multiple cranial nerves due to a rare p.(Phe84Ser) variant. Transl Neurosci. 2022;13:116\u20139.","journal-title":"Transl Neurosci."},{"key":"3281_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/humu.23669","volume":"40","author":"D Rowczenio","year":"2019","unstructured":"Rowczenio D, Quarta CC, Fontana M, et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 2019;40:90\u20136.","journal-title":"Hum Mutat"},{"key":"3281_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/13506129.2022.2142110","volume":"30","author":"F de Frutos","year":"2023","unstructured":"de Frutos F, Ochoa JP, G\u00f3mez-Gonz\u00e1lez C, et al. Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain. Amyloid. 2023;30:199\u2013207.","journal-title":"Amyloid"},{"key":"3281_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001755","volume":"8","author":"RE Lauppe","year":"2021","unstructured":"Lauppe RE, Liseth Hansen J, Gerdesk\u00f6ld C, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8: e001755.","journal-title":"Open Heart"},{"key":"3281_CR17","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ehf2.13961","volume":"9","author":"R Lauppe","year":"2022","unstructured":"Lauppe R, Liseth Hansen J, Fornwall A, et al. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries. ESC Heart Fail. 2022;9:2528\u201337.","journal-title":"ESC Heart Fail"},{"key":"3281_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/genes12081152","volume":"12","author":"Z Pozsonyi","year":"2021","unstructured":"Pozsonyi Z, Pesk\u00f3 G, Tak\u00e1cs H, et al. Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features. Genes (Basel). 2021;12:1152.","journal-title":"Genes (Basel)"},{"key":"3281_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:1677\u201396.","journal-title":"Eur J Heart Fail"},{"key":"3281_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, Razvi Y, Masi A, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25:515\u201324.","journal-title":"Eur J Heart Fail"},{"key":"3281_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","volume":"26","author":"M Bruno","year":"2021","unstructured":"Bruno M, Casta\u00f1o A, Burton A, et al. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26:35\u201345.","journal-title":"Heart Fail Rev"},{"key":"3281_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2022.12.048","volume":"374","author":"M Prasad","year":"2023","unstructured":"Prasad M, Kim M, Chandrashekar P, et al. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women. Int J Cardiol. 2023;374:116\u20139.","journal-title":"Int J Cardiol"},{"key":"3281_CR23","doi-asserted-by":"crossref","unstructured":"Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"3281_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaccao.2020.10.007","volume":"2","author":"S Arora","year":"2020","unstructured":"Arora S, Patil NS, Strassle PD, et al. Amyloidosis and 30-day outcomes among patients with heart failure. JACC CardioOncol. 2020;2:710\u20138.","journal-title":"JACC CardioOncol"},{"key":"3281_CR25","doi-asserted-by":"crossref","unstructured":"Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.","DOI":"10.1161\/JAHA.113.000098"},{"key":"3281_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","volume":"17","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Coelho T, Concei\u00e7\u00e3o I, et al. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022;17:236.","journal-title":"Orphanet J Rare Dis"},{"key":"3281_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.recesp.2021.07.007","volume":"75","author":"J \u00c1lvarez Rubio","year":"2022","unstructured":"\u00c1lvarez Rubio J, Manovel S\u00e1nchez AJ, Gonz\u00e1lez-Costello J, et al. Caracterizaci\u00f3n de la amiloidosis cardiaca hereditaria por transtirretina en Espa\u00f1a. Rev Esp Cardiol. 2022;75:488\u201395.","journal-title":"Rev Esp Cardiol"},{"key":"3281_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.regg.2018.04.277","volume":"53","author":"R Ayala Mu\u00f1oz","year":"2018","unstructured":"Ayala Mu\u00f1oz R, Jaramillo Hidalgo J, Aranda Rubio Y, et al. Prevalencia de amiloidosis por transtirretina (TTR) en pacientes con insuficiencia cardiaca con fracci\u00f3n de eyecci\u00f3n preservada. Rev Esp Geriatr Gerontol. 2018;53:114.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"3281_CR29","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","volume":"27","author":"G Vergaro","year":"2020","unstructured":"Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020;27:1806\u201315.","journal-title":"Eur J Prev Cardiol"},{"key":"3281_CR30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442\u20138.","journal-title":"Heart"},{"key":"3281_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44156-023-00028-7","volume":"10","author":"WE Moody","year":"2023","unstructured":"Moody WE, Turvey-Haigh L, Knight D, et al. British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Res Pract. 2023;10:13.","journal-title":"Echo Res Pract"},{"key":"3281_CR32","doi-asserted-by":"crossref","unstructured":"Glavam AP, Lopes RW, Brand\u00e3o SCS. My approach to imaging cardiac amyloidosis: role of bone-seeking tracers scintigraphy. Arq Bras Cardiol: Imagem Cardiovasc. 2023;36(2):e20230012.","DOI":"10.36660\/abcimg.20230012i"},{"issue":"2","key":"3281_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195\u2013201.","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03281-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03281-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03281-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T05:03:55Z","timestamp":1721451835000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03281-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3281"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03281-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4021958\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HCFMUSP Ethics Committee approved this study, and written informed consent was waived. (CAAE: 53302721.5.1001.0068; Approval report No. 5.188.324).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}